Identification of genes involved in enzalutamide-resistant prostate cancer

Enzalutamide is the second generation of prostatic hormonal medications and is used to treat docetaxel resistance patients in advanced prostate cancer. This drug reduces their growth inhibitory effect on testosterone (a hormone required to grow cancer cells). The purpose of this study was to identify the genes involved in prostatecancer in treatment with enzalutamide and dihydrotestosterone, to investigate their gene ontology and identifying the genes involved in the key pathways of cancer. In this study, data on enzalutamide and DHT were extracted from NCBI GEO and analyzed using Flexarray software, Expression Console, and altered genes were detected by treatment with enzalutamide and DHT. Also, by examining the gene ontology, the biological processes involved were also identified. Based on the analysis, 29 genes were reduced by DHT treatment and decreased by 30 genes, which are involved in biological processes of cellular expansion and cell differentiation, adjustment of homeostasis, and endothelial cell migration regulation, respectively. 22 genes were treated with dihydrotestosterone and enzalutamide, increased expression and 33 genes decreasing expression, which play a role in biological processes for cell death and cell migration, respectively. Information from biological processes showed that dihydrotestosterone alone led to an increase in cancer and, when treated with enzalutamide, reduced cancer by activating the processes involved in apoptosis.

کلیدواژه ها:

Enzalutamide ، Dihydrotestosterone ، Gene ontology